Fw: Top 10 countdown

[Guest guest]

The Lancet Top 10 Countdown

Top 10 countdown

Top 10 most requested

papers from The Lancet

Seminar: Alzheimer's disease

Blennow, K.; de Leon, M.J.; Zetterberg, H.

The Lancet 29 July 2006; 368(9533): 387-403

Article: Effect of rosiglitazone on the frequency of

diabetes in patients with impaired glucose tolerance or impaired fasting

glucose: a randomised controlled trial

The DREAM Trial Investigators

The Lancet 23 Sept 2006; 368(9541); 1096-1105

Article: Aspirin plus dipyridamole versus aspirin alone

after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled

trial

The ESPRIT Study Group

The Lancet 20 May 2006; 367(9523):1665-1673

New Drug Class: The incretin system: glucagon-like

peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2

diabetes

Drucker, D.J.; Nauck, M.A.

The Lancet 11 Nov 2006; 368(9548):1696-1705

Article: Clopidogrel plus aspirin versus oral

anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel

Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised

controlled trial

The ACTIVE Writing Group on behalf of the ACTIVE

Investigators

The Lancet 10 Jun 2006; 367(9526): 1903-1912

Article: Efficacy and safety of cholesterol-lowering

treatment: prospective meta-analysis of data from 90 056 participants in 14

randomised trials of statins

Cholesterol Treatment Trialists (CTT) Callaborators

The Lancet 08 Oct 2005; 366(9493): 1267-1278

Article: Efficacy and tolerability of rimonabant in

overweight or obese patients with type 2 diabetes: a randomised controlled study

For the RIO-Diabetes Study Group; Scheen, A.J.; Finer,

N.;

Hollander, P.; Jensen, M.D.; Van Gaal, L.F.

The Lancet 11 Nov 2006; 368(9548): 1660-1672

Seminar: Gastro-oesophageal reflux disease

Moayyedi, P.; Talley, N.J.

The Lancet 24 Jun 2006; 367(9528): 2086-2100

Article: 12-h pretreatment with methylprednisolone

versus placebo for prevention of postextubation laryngeal oedema: a randomised

double-blind trial

For the Association des Reanimateurs du Centre-Ouest

(ARCO); Francois, B.; Bellissant, E.; Gissot, V.; Desachy, A.; Normand, S.;

Boulain, T.; Brenet, O.; Preux, P.M.; Vignon, P.

The Lancet 31 Mar 2007; 369(9567): 1083-1089

Article: Safety and efficacy of the HIV-1 integrase

inhibitor raltegravir (MK-0518) in treatment-experienced patients with

multidrug-resistant virus: a phase II randomised controlled trial

For the Protocol 005 Team; Grinsztejn, B.; Nguyen, B.Y.;

Katlama, C.; Gatell, J.M.; Lazzarin, A.; Vittecoq, D.; , C.J.; Chen, J.;

Harvey, C.M.; Isaacs, R.D.

The Lancet 14 Apr 2007; 369(9569): 1261-1269

Three ways to access these papers in

full-text:

1. Ihave a subscription

Access the full-text articles with your subscription

Log in here

2. Ido not have a subscription

Pay-per-view articles are available for purchase at

thelancet.com

3. Iwant a subscription

Subscribe to The Lancet

for full-content access

Click here

This e-mail has been sent from The Lancet, Elsevier Inc., 360 Park

Avenue South; New York, NY 10010; USA. Please do not reply to this email as it

is post-only and cannot be read.

You received this email because you have requested to receive

special event alerts from The Lancet at thelancet.com . Tounsubscribe, click

herehttp://www.thelancet.com/account/alerts to update your profile - simply log

in with your username and password, and amend your preferences.

The Lancet respects your privacy and does not disclose, rent or sell

your personal information to any non-affiliated third parties without your

consent, except as may be stated in our Privacy Policy. For more information,

visit http://www.thelancet.com/misc/privacypop.

Copyright 2007 Elsevier Inc. All rights reserved.

THE LANCET® is a registered trademark of Elsevier Properties S.A.

used under license.